Clinical trials: Mental Disorder, Child
Childhood-Onset Fluency Disorder (Stuttering)
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.
- Trial name
- NCT04492956
- Testing
- Ecopipam
- Where
- 9 sites in United States
- Volunteers
- 68 people
- Sponsor
- Emalex Biosciences Inc.
Anorexia Nervosa, Constipation
The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa
The aim of this study is to investigate whether Lactobacillus reuteri could have a beneficial role in treatment of children and adolescents with Anorexia nervosa who develop motility disorder due to the malnutrition regarding the…
- Trial name
- NCT02004288
- Testing
- Lactobacillus reuteri Protectis DSM17938
- Where
- Croatia
- Volunteers
- 31 people
- Sponsor
- BioGaia AB
Mental Retardation, Developmental Delay
Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)
Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of Sanfilippo Disease Type A-B-C-D from blood (plasma)
- Trial name
- BioSanfilippo (NCT02298686)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Parenting Practices, Self Efficacy
Talk Parenting Education Program II
The goal of this clinical trial is to learn whether Talk Parenting, a voice-based program delivered through an Amazon Echo Dot (Alexa), can help parents and caregivers of children ages 3-5 years improve challenging bedtime and…
- Conditions
- Parenting Practices, Self Efficacy, Stress, Child Behavior
- Trial name
- TP2 (NCT07462052)
- Testing
- The Talk Parenting Program
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Attention Deficit Hyperactivity Disorder
CONCERTA Lab School Study
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT00799487
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Autism
A Trial of CM-AT in Children With Autism
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.
- Trial name
- CM-AT (NCT00881452)
- Testing
- CM-AT
- Where
- 19 sites in United States
- Volunteers
- 182 people
- Sponsor
- Curemark
Attention-Deficit/Hyperactivity Disorder
Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00640185
- Testing
- ABT-089
- Where
- 12 sites in United States
- Volunteers
- 160 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
ADHD
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting
- Trial name
- NCT00697515
- Testing
- LDX
- Where
- 5 sites in United States
- Volunteers
- 142 people
- Sponsor
- Shire
Attention-Deficit/Hyperactivity Disorder
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT02163915
- Testing
- TAK-137
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Takeda
Conduct Disorder, Disruptive Behavior Disorder
A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the effectiveness and safety of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of conduct disorder in children with mild, moderate, or…
- Conditions
- Conduct Disorder, Disruptive Behavior Disorder, Oppositional Defiant Disorder
- Trial name
- NCT00266552
- Testing
- risperidone
- Volunteers
- 118 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Attention Deficit Hyperactivity Disorder (ADHD)
A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life
The main aim of the study is to find out how frequently adults with at least one psychiatric condition have ADHD (but have not been diagnosed with ADHD before) and to describe the quality of life of these adults who have been…
- Trial name
- LANDSCAPE (NCT04943796)
- Where
- 14 sites in Canada, Germany and 4 more
- Volunteers
- 224 people
- Sponsor
- Takeda
Attention Deficit Hyperactivity Disorder
Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
- Trial name
- NCT00434213
- Testing
- Daytrana
- Where
- 29 sites in United States
- Volunteers
- 309 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01244490
- Testing
- Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride
- Where
- 66 sites in United States, Austria and 11 more
- Volunteers
- 338 people
- Sponsor
- Shire
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Attention Deficit Hyperactivity Disorder
Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD
The purpose of the study is to compare atomoxetine hydrochloride and methylphenidate hydrochloride in pediatric patients with ADHD.
- Trial name
- NCT00486083
- Testing
- Atomoxetine Hydrochloride, Methylphenidate Hydrochloride
- Where
- 3 sites in China, Mexico and 1 more
- Volunteers
- 330 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Autistic Disorder
Study of Fluoxetine in Autism
The purpose of this study is to assess the effect of fluoxetine orally dissolving tablets (ODT) on the repetitive behaviors core domain in children and adolescents with Autistic Disorder.
- Trial name
- SOFIA (NCT00515320)
- Testing
- Fluoxetine
- Where
- 17 sites in United States
- Volunteers
- 158 people
- Sponsor
- Neuropharm
Nocturnal Enuresis
Overnight Pant Study for Children With Nocturnal Enuresis
This study will evaluate the in-use tolerance of an absorbent disposable underwear pant developed for children with nocturnal enuresis by assessing adverse events.
- Trial name
- NCT05178641
- Testing
- Ninjamas Pyjama Pants, Participant's Overnight Current Standard of Care
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.